Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited (ZLAB) is a research-based, commercial-stage biopharmaceutical company based in China and the United States, with a focus on oncology, immunology, neuroscience, and infectious disease. The Zai Lab news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones, and financial disclosures that the company releases through channels such as Business Wire and SEC filings.
Investors and followers of ZLAB stock can use this page to review news on Zai Lab’s global pipeline, including progress of assets like zocilurtatug pelitecan (zoci), a DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer and other neuroendocrine carcinomas, and ZL-1503, an IL-13/IL-31R bispecific antibody for atopic dermatitis. Updates on other oncology and immunology programs, such as ZL-6201, ZL-1222, and ZL-1311, also appear in company press releases.
The news stream highlights regulatory developments in Greater China, including National Medical Products Administration (NMPA) approvals and National Reimbursement Drug List (NRDL) decisions for products in Zai Lab’s commercial portfolio. Recent examples include announcements about COBENFY for schizophrenia and AUGTYRO for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors, as well as renewals and coverage decisions for VYVGART, NUZYRA, and ZEJULA.
In addition, this page surfaces Zai Lab’s financial result releases, conference call notices, and participation in healthcare and investor conferences. These items provide context on revenue trends, R&D spending, and the company’s dual-engine strategy combining a China commercial business with a global innovation platform. Bookmark this page to quickly access ZLAB-related news, organized in one place for efficient review of the company’s ongoing clinical, regulatory, and corporate developments.
Zai Lab (NASDAQ: ZLAB) and Turning Point Therapeutics announced encouraging topline results from the Phase 1/2 TRIDENT-1 study of repotrectinib in China. The study demonstrated a 91% confirmed objective response rate (cORR) in the TKI-naïve cohort, with a duration of response (DOR) follow-up of 3.7 months. In three TKI-pretreated cohorts, cORR ranged from 36%-67%. Zai Lab plans to discuss these results with Chinese health authorities in Q4 2022, aiming to advance their regulatory pathway. The TRIDENT-1 study continues to enroll patients globally.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has engaged KPMG as its independent registered public accounting firm to facilitate compliance with U.S. audit requirements under the Holding Foreign Companies Accountable Act. This strategic move aims to ensure the company's continued listing on Nasdaq. The engagement of KPMG, based in the United States, will cover annual consolidated financial statements and internal controls over financial reporting for the fiscal year ending December 31, 2022. The transition was amicable, with no unresolved issues with the previous auditor.
Zai Lab Limited (NASDAQ: ZLAB) has announced it will report its financial results for Q1 2022 on May 10, 2022, following market close. The company will host a conference call and webcast on May 11, 2022, at 8:00 a.m. ET. Zai Lab is focused on developing therapies for unmet medical needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. It aims to become a leading global biopharmaceutical company through innovative product development and strategic partnerships.
Zai Lab Limited (NASDAQ: ZLAB) is set to present groundbreaking data on its oncology pipeline at the 2022 AACR Annual Meeting in New Orleans from April 8-13, 2022. Key highlights include the first preview of preclinical data for ZL-1218, an anti-CCR8 antibody targeting solid tumors, along with additional candidates like ZL-1201 and ZL-1211 for various cancers. The oral presentation will take place on April 12, 2022, showcasing promising therapeutic developments. Zai Lab emphasizes its commitment to advancing cancer treatments globally, addressing significant unmet medical needs.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced an extraordinary general meeting (EGM) to be held virtually on March 28, 2022, at 8:00 a.m. Eastern Time. This change is due to COVID-19 restrictions in Shanghai. Shareholders will vote on a proposal for a 1-to-10 share subdivision. Shareholders of record may attend the meeting virtually using a control number found on their proxy materials. The EGM format has been updated, but prior proxy materials remain valid for voting.
Zai Lab Limited (NASDAQ: ZLAB) presented Phase 3 PRIME study results at the Society of Gynecologic Oncology annual meeting, revealing that ZEJULA (niraparib) significantly improved progression-free survival (PFS) in patients with advanced ovarian cancer. The median PFS for niraparib was 24.8 months compared to 8.3 months for placebo. Treatment was well-tolerated, with a low discontinuation rate due to adverse events (less than 7%). This data supports niraparib as a standard maintenance therapy after platinum-based chemotherapy in China.
Zai Lab Limited (NASDAQ: ZLAB) announced the appointment of Josh Smiley as Chief Operating Officer (COO) effective August 1, 2022. With over 26 years of biopharmaceutical experience, he previously held leadership roles at Eli Lilly. CEO Dr. Samantha Du emphasized Smiley's leadership expertise as essential for Zai Lab's growth and operational excellence. His appointment comes during a pivotal time for Zai Lab, with significant opportunities in their pipeline aimed at expanding geographically and diversifying their financial base.
Zai Lab Limited (NASDAQ: ZLAB) reported strong financial growth for 2021, achieving net product revenues of $144.1 million compared to $49.0 million in 2020. Key drivers included a 200% increase in ZEJULA revenue and significant advancements in its product pipeline, including proof of concept for ZL-1102. R&D expenses increased to $573.3 million due to new licensing agreements and clinical trials. The company plans to submit new drug applications and expects substantial revenue growth, projecting peak-year sales of $2.5 to $3 billion by 2030.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that its investigational drug repotrectinib received Breakthrough Therapy Designation from the NMPA for treating ROS1-positive metastatic non-small-cell lung cancer (NSCLC) in patients who haven't received ROS1 TKI treatment. The Phase 1/2 TRIDENT-1 study provided initial data supporting this designation. Repotrectinib targets ROS1 and NTRK mutations and may be the best-in-class therapy, offering hope for patients in need, especially in a region with high lung cancer incidence.
Zai Lab Limited (ZLAB) will announce its financial results for the year ended December 31, 2021, after U.S. market close on March 1, 2022. A conference call and webcast will be held on March 2, 2022, at 8:00 a.m. ET. Participants must register in advance to receive access details. Zai Lab is focused on developing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience. The company aims to innovate and commercialize products addressing unmet medical needs globally.